Abbott Integrates Four Precision Oncology Tests into Flatiron’s OncoEMR for 4,700 Providers
Abbott integrated its Precision Oncology portfolio, including Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect and Riskguard tests, into Flatiron Health’s OncoEMR platform, granting 1,600 community cancer centers and 4,700 providers direct digital access within their clinical workflows. This integration accelerates informed treatment decisions and reduces administrative burden.
1. Integration of Precision Oncology Tests
Abbott’s comprehensive portfolio of Precision Oncology tests—including Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect and Riskguard—has been embedded into Flatiron’s OncoEMR platform, enabling oncologists to digitally order individual or combined assays and receive status updates and results within their existing EMR workflow.
2. Expanded Network Access
The integration immediately extends Abbott’s test availability to more than 1,600 community cancer care centers and 4,700 oncology providers across Flatiron’s North American network, which represents a majority of U.S. cancer treatment settings.
3. Clinical and Operational Benefits
By delivering test ordering and results directly in the clinical workflow, this unified experience aims to accelerate treatment decision timelines, reduce administrative burdens and support more personalized, data-driven care at the point of oncology treatment.